Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR)

References

• Toton E, Lisiak N, Sawicka P, et al. Beclin-1 and its role as a target for anticancer therapy. J Physiol Pharmacol. 2014;65:459–467.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanzawa T, Sawaya R, et al. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5:726–734.
   PubMed Web of Science ®Google Scholar
• Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961–967.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809–1820.
   PubMed Web of Science ®Google Scholar
• Yang Z, Ghoorun RA, Fan X, et al. High expression of Beclin-1 predicts favorable prognosis for patients with colorectal cancer. Clin Res Hepatol Gastroenterol. 2015;39:98–106.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim HS, Cho H, et al. Clinicopathologic correlation of autophagy-related Beclin-1 expression in gallbladder cancer. Hepatogastroenterol. 2014;61:1494–1500.
   PubMed Web of Science ®Google Scholar
• Cai M, Hu Z, Liu J, et al. Beclin 1 expression in ovarian tissues and its effects on ovarian cancer prognosis. Int J Mol Sci. 2014;15:5292–5303.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Koutsopoulos A, et al. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol Oncol. 2011;123:147–151.
   PubMed Web of Science ®Google Scholar
• Cha YJ, Kim YH, Cho NH, et al. Expression of autophagy related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma. Int J Clin Exp Pathol. 2014;7:3389–3398.
   PubMed Web of Science ®Google Scholar
• Nicotra G, Mercalli F, Peracchio C, et al. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol. 2010;41:107–112.
   PubMed Web of Science ®Google Scholar
• Huang JJ, Li HR, Huang Y, et al. Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy. 2010;6:777–783.
   PubMed Web of Science ®Google Scholar
• Nicotra G, Mercalli F, Peracchio C, et al. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. Mod Pathol. 2010;23:937–950.
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117:326–336.
   PubMed Web of Science ®Google Scholar
• Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 2011;117:5573–5581.
   PubMed Web of Science ®Google Scholar
• Tucci M, Stucci S, Savonarola A, et al. An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. Exp Hematol. 2014;42:897–908.
   PubMed Web of Science ®Google Scholar
• Hoang B, Benavides A, Shi Y, et al. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009;8:1974–1984.
   PubMed Web of Science ®Google Scholar
• Niewerth D, Jansen G, Assaraf YG, et al. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015;18:18–35.
   PubMed Web of Science ®Google Scholar
• Abdel Malek MA, Jagannathan S, Malek E, et al. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget. 2015;6:3098–3110.
   PubMed Web of Science ®Google Scholar
• Kern J, Untergasser G, Zenzmaier C, et al. GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood. 2009;114:3960–3967.
   PubMed Web of Science ®Google Scholar
• Rasche L, Duell L, Castro IC, et al. GRP78-directed Immunotherapy in relapsed or refractory multiple myeloma – results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica. 2015;100:377–384.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Stadtmauer EA, Tan KS, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014;10:1380–1390.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin[clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall response rates in treatment-naïve symptomatic multiple myeloma. Blood. 2008;111:1101–1109.
   PubMed Web of Science ®Google Scholar
• Coleman M, Leonard J, Lyons L, et al. Blt-d (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström’s macroglobulinemia. Leuk Lymphoma. 2002;43:1777–1782.
   PubMed Web of Science ®Google Scholar
• Jöhrer K, Obkircher M, Neureiter D, et al. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target. J Mol Med (Berl). 2012;90:681–693.
   PubMed Web of Science ®Google Scholar
• McKenna RW, Kyle RA, Kuehl WM, et al. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoetic and lymphoid tissues. Lyon: IARC; 2008. p. 200–213.
   Google Scholar
• International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Moreau P, Cavo M, Sonneveld P, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32:2173–2180.
   PubMed Web of Science ®Google Scholar
• Pan Y, Gao Y, Chen L, et al. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res. 2011;17:3248–3258.
   PubMed Web of Science ®Google Scholar
• Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol. 2013;13:722–737.
   PubMed Web of Science ®Google Scholar
• Oliva L, Cenci S. Autophagy in plasma cell pathophysiology. Front Immunol. 2014;5:103
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544–1552.
   PubMed Web of Science ®Google Scholar
• Jung G, Roh J, Lee H, et al. Autophagic markers BECLIN 1 and LC3 are associated with prognosis of multiple myeloma. Acta Haematol. 2015;134:17–24.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kikukawa Y, Takeya M, et al. Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol. 2010;37:815–820.
   PubMed Web of Science ®Google Scholar
• Martiniani R, Di Loreto V, Di Sano C, et al. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol. 2012;2012:842945.
   PubMedGoogle Scholar
• Pessoa de Magalhães RJ, Vidriales MB, Paiva B, et al. Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98:79–86.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Nguyen TM, Subramanian IV, et al. Autophagy and angiogenesis inhibition. Autophagy. 2007;3:512–515.
   PubMed Web of Science ®Google Scholar
• Willenbacher W, Willenbacher E, Zelle-Rieser C, et al. Bone marrow micro-environmental CD4+ and CD8+ lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma – an analysis from the Austrian Myeloma Registry (AMR). Leuk Lymphoma. 2015. doi: 10.3109/10428194.2015.1099646. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar